Adventures in Capitalism: Outcry Over EpiPen Prices Hasn’t Made Them Lower

https://www.nytimes.com/2017/06/04/business/angry-about-epipen-prices-executive-dont-care-much.html?partner=rss&emc=rss

Mylan has an effective monopoly on a lifesaving product, which has allowed its leaders to see public outrage as a tax they must pay.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s